• 011-26907444
  • raghava@iiitd.ac.in

Welcome to Peptide Card of AntiTbPdb

This page displays user query in tabular form.

fkcrrwqwrmkklg details
Primary information
ID antitb_1171,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2447 smooth transparent variant (SmT)
Cell LineIC50 = 14.2 ± 1.5
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1172,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2447 smooth transparent variant (SmT)
Cell LineIC90 = 18.9 ± 4.0
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1173,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2-151 smooth transparent variant (SmT)
Cell LineIC50 = 8.0 ± 1.5
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1174,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2-151 smooth transparent variant (SmT)
Cell LineIC90 = 22.8 ± 9.1
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1175,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2-151 smooth doomed variant (SmD)
Cell LineIC50 = 12.4 ± 0.3
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1176,
Name24709266
N-Terminal modificationLFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesProtein Derived
StrainFrom bovine lactoferricin
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2-151 smooth doomed variant (SmD)
Cell LineIC90 = 21.5 ± 4.0
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationAntibacterial
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1177,
Name24709266
N-Terminal modificationD-LFcin17-30
C-Terminal Modificationfkcrrwqwrmkklg
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceD
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2447 smooth transparent variant (SmT)
Cell LineIC50 = 10.7 ± 0.9
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationNone
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1178,
Name24709266
N-Terminal modificationD-LFcin17-30
C-Terminal Modificationfkcrrwqwrmkklg
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceD
OriginCationic
SpeciesSynthetic
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium strain 2447 smooth transparent variant (SmT)
Cell LineIC90 = 14.4 ± 1.9
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNone
In vivo ModelNA
Lethal DoseNA
Immune ResponceNone
Mechanism of ActionNA
TargetNA
Combination TherapyPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.
Other activitiesCell envelope
PMIDNone
Year of PublicationNone
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1545,
Name25613372
N-Terminal modificationD-LFcin17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
Inhibition ConcentrationMycobacterium tuberculosis
In Vitro/ In vivoMycobacterium tuberculosis H37Rv
Cell Line14.4 μg/ml
Inhibition Concentrationin vitro
Sequence2015
CytotoxicityNA
In vivo ModelNA
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
Targetinduce expression of IFN-γ
Combination TherapyCause structural damage to mycobacteria
Other activitiesNA
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1900,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2447 smT
Cell LineIC50 = 14.2 ± 1.5 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 50% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1901,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2447 smT
Cell LineIC90 = 18.9 ± 4.0 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 90% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1902,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2-151 smT
Cell LineIC50 = 8.0 ± 1.5 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 50% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1903,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2-151 smT
Cell LineIC90 = 22.8 ± 9.1 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 90% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1904,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2-151 smD
Cell LineIC50 = 12.4± 0.3 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 50% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1905,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceL
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium 2-151 smD
Cell LineIC90 = 21.5± 4.0 μM
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 90% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1906,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceD
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium
Cell LineMycobacterium avium 2447 smT
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 50% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),
Primary information
ID antitb_1907,
Name24709266
N-Terminal modificationBovine lactoferricin 17-30
C-Terminal ModificationFKCRRWQWRMKKLG
Chemical ModificationFree
Linear/CyclicFree
LengthNone
ChiralityLinear
Nature14
SourceD
OriginCationic
SpeciesNatural
StrainDerived from bovine lactoferricin protein
Inhibition ConcentrationMycobacterium avium
In Vitro/ In vivoMycobacterium avium
Cell LineMycobacterium avium 2447 smT
Inhibition ConcentrationIn vitro
Sequence2014
CytotoxicityNA
In vivo ModelTratment with this concentration inhibit 90% bacterial growth
Lethal DoseNA
Immune ResponceNA
Mechanism of ActionNA
TargetNA
Combination TherapyNA
Other activitiesLipid bilayer
PMIDNA
Year of PublicationNA
Tertiary Structure
(Technique)
Not Predicted),